secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001193125-25-280172
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics Q3 2025 net loss $18.2M, cash $134.4M to fund into Q2 2027
-------------------------------------------------------------------------------

- Net loss of $18.2M for Q3 2025, improved from $22.4M in Q3 2024.
- Cash, cash equivalents and investments of $134.4M as of Sep 30, 2025; funds operations into Q2 2027.
- R&D expenses fell to $13.6M from $18.9M due to fewer milestones and trial prioritization.
- Advancing ACR-368 Phase 2b trial for endometrial cancer; initial ACR-2316 Phase 1 data expected H2 2025.
- Presented AP3 platform data at AACR-NCI-EORTC; new cell cycle program targets candidate nomination in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/0001193125-25-280172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000119312525280172/acrv-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-280172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer